

# Violetta Cecchetti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1705110/publications.pdf>

Version: 2024-02-01

118  
papers

3,379  
citations

117571

34  
h-index

197736

49  
g-index

124  
all docs

124  
docs citations

124  
times ranked

3644  
citing authors

#	ARTICLE	IF	CITATIONS
1	Broad-Spectrum Anti-Flavivirus Activity and Chemistry of Compounds Containing Sulfur and Oxygen Chalcogens. <i>Current Medicinal Chemistry</i> , 2023, 30, 2396-2420.	1.2	3
2	Triazolopyrimidine Nuclei: Privileged Scaffolds for Developing Antiviral Agents with a Proper Pharmacokinetic Profile. <i>Current Medicinal Chemistry</i> , 2022, 29, 1379-1407.	1.2	3
3	Discovery of 2-Phenylquinolines with Broad-Spectrum Anti-coronavirus Activity. <i>ACS Medicinal Chemistry Letters</i> , 2022, 13, 855-864.	1.3	10
4	Sustainable, three-component, one-pot procedure to obtain active anti-flavivirus agents. <i>European Journal of Medicinal Chemistry</i> , 2021, 210, 112992.	2.6	6
5	Inhibition of Influenza Virus Polymerase by Interfering with Its Protein-Protein Interactions. <i>ACS Infectious Diseases</i> , 2021, 7, 1332-1350.	1.8	18
6	Synthesis and characterization of 1,2,4-triazolo[1,5-a]pyrimidine-2-carboxamide-based compounds targeting the PA-PB1 interface of influenza A virus polymerase. <i>European Journal of Medicinal Chemistry</i> , 2021, 209, 112944.	2.6	17
7	From Quinoline to Quinazoline-Based <i>S. aureus</i> NorA Efflux Pump Inhibitors by Coupling a Focused Scaffold Hopping Approach and a Pharmacophore Search. <i>ChemMedChem</i> , 2021, 16, 3044-3059.	1.6	9
8	1,2,4-Triazolo[1,5-a]pyrimidines: Efficient one-step synthesis and functionalization as influenza polymerase PA-PB1 interaction disruptors. <i>European Journal of Medicinal Chemistry</i> , 2021, 221, 113494.	2.6	15
9	Structural Modifications of the Quinolin-4-yloxy Core to Obtain New <i>Staphylococcus aureus</i> NorA Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7037.	1.8	8
10	Broad-Spectrum Flavivirus Inhibitors: a Medicinal Chemistry Point of View. <i>ChemMedChem</i> , 2020, 15, 2391-2419.	1.6	25
11	Modulating microRNA Processing: Enoxacin, the Progenitor of a New Class of Drugs. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 12275-12289.	2.9	20
12	Antitubercular polyhalogenated phenothiazines and phenoselenazine with reduced binding to CNS receptors. <i>European Journal of Medicinal Chemistry</i> , 2020, 201, 112420.	2.6	12
13	1,2,4-Triazolo[1,5-a]pyrimidines as a Novel Class of Inhibitors of the HIV-1 Reverse Transcriptase-Associated Ribonuclease H Activity. <i>Molecules</i> , 2020, 25, 1183.	1.7	23
14	Pyridobenzothiazolones Exert Potent Anti-Dengue Activity by Hampering Multiple Functions of NS5 Polymerase. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 773-782.	1.3	28
15	C-2 phenyl replacements to obtain potent quinoline-based <i>Staphylococcus aureus</i> NorA inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2020, 35, 584-597.	2.5	13
16	New Insights on KCa3.1 Channel Modulation. <i>Current Pharmaceutical Design</i> , 2020, 26, 2096-2101.	0.9	4
17	Deciphering the Molecular Recognition Mechanism of Multidrug Resistance <i>Staphylococcus aureus</i> NorA Efflux Pump Using a Supervised Molecular Dynamics Approach. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4041.	1.8	18
18	Discovery of potent p38 MAPK inhibitors through a funnel like workflow combining in silico screening and in vitro validation. <i>European Journal of Medicinal Chemistry</i> , 2019, 182, 111624.	2.6	17

#	ARTICLE	IF	CITATIONS
19	Engagement of Nuclear Coactivator 7 by 3-Hydroxyanthranilic Acid Enhances Activation of Aryl Hydrocarbon Receptor in Immunoregulatory Dendritic Cells. <i>Frontiers in Immunology</i> , 2019, 10, 1973.	2.2	47
20	Modifications on C6 and C7 Positions of 3-Phenylquinolone Efflux Pump Inhibitors Led to Potent and Safe Antimycobacterial Treatment Adjuvants. <i>ACS Infectious Diseases</i> , 2019, 5, 982-1000.	1.8	10
21	Broad spectrum anti-flavivirus pyridobenzothiazolones leading to less infective virions. <i>Antiviral Research</i> , 2019, 167, 6-12.	1.9	24
22	Co-crystal structure determination and cellular evaluation of 1,4-dihydropyrazolo[4,3-c] [1,2] benzothiazine 5,5-dioxide p38 $\beta$ MAPK inhibitors. <i>Biochemical and Biophysical Research Communications</i> , 2019, 511, 579-586.	1.0	6
23	From cycloheptathiophene-3-carboxamide to oxazinone-based derivatives as allosteric HIV-1 ribonuclease H inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2019, 34, 55-74.	2.5	16
24	Advantageous Use of Ionic Liquids for the Synthesis of Pharmaceutically Relevant Quinolones. <i>European Journal of Organic Chemistry</i> , 2018, 2018, 2977-2983.	1.2	10
25	A Comprehensive Structural Overview of p38 $\beta$ Mitogen-Activated Protein Kinase in Complex with ATP $\beta$ Site and Non-ATP $\beta$ Site Binders. <i>ChemMedChem</i> , 2018, 13, 7-14.	1.6	20
26	Functionalized 2,1-benzothiazine 2,2-dioxides as new inhibitors of Dengue NS5 RNA-dependent RNA polymerase. <i>European Journal of Medicinal Chemistry</i> , 2018, 143, 1667-1676.	2.6	24
27	2-Phenylquinoline <i>S. aureus</i> NorA Efflux Pump Inhibitors: Evaluation of the Importance of Methoxy Group Introduction. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 7827-7848.	2.9	46
28	Studies on 2-phenylquinoline <i>Staphylococcus aureus</i> NorA efflux pump inhibitors: New insights on the C-6 position. <i>European Journal of Medicinal Chemistry</i> , 2018, 155, 428-433.	2.6	19
29	Pharmacophore-Based Repositioning of Approved Drugs as Novel <i>Staphylococcus aureus</i> NorA Efflux Pump Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1598-1604.	2.9	59
30	Searching for Novel Inhibitors of the <i>S. aureus</i> NorA Efflux Pump: Synthesis and Biological Evaluation of the 3-Phenyl-1,4-benzothiazine Analogues. <i>ChemMedChem</i> , 2017, 12, 1293-1302.	1.6	28
31	Exploring the cycloheptathiophene-3-carboxamide scaffold to disrupt the interactions of the influenza polymerase subunits and obtain potent anti-influenza activity. <i>European Journal of Medicinal Chemistry</i> , 2017, 138, 128-139.	2.6	38
32	Structure-Activity Relationships on Cinnamoyl Derivatives as Inhibitors of p300 Histone Acetyltransferase. <i>ChemMedChem</i> , 2017, 12, 1359-1368.	1.6	11
33	Efficient and regioselective one-step synthesis of 7-aryl-5-methyl- and 5-aryl-7-methyl-2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivatives. <i>Organic and Biomolecular Chemistry</i> , 2017, 15, 7944-7955.	1.5	31
34	Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against <i>Mycobacterium avium</i> . <i>European Journal of Medicinal Chemistry</i> , 2017, 140, 321-330.	2.6	28
35	Investigation on the effect of known potent <i>S. aureus</i> NorA efflux pump inhibitors on the staphylococcal biofilm formation. <i>RSC Advances</i> , 2017, 7, 37007-37014.	1.7	33
36	The $\alpha$ -ceramic approach in the evaluation of the enantiomeric NorA efflux pump inhibition activity of 2-phenylquinoline derivatives. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 129, 182-189.	1.4	14

#	ARTICLE	IF	CITATIONS
37	Studies on Cycloheptathiophene-3-carboxamide Derivatives as Allosteric HIV-1 Ribonuclease-H Inhibitors. <i>ChemMedChem</i> , 2016, 11, 1709-1720.	1.6	15
38	Targeting flavivirus RNA dependent RNA polymerase through a pyridobenzothiazole inhibitor. <i>Antiviral Research</i> , 2016, 134, 226-235.	1.9	49
39	Bicyclic octahydrocyclohepta[ b ]pyrrol-4(1 H)one derivatives as novel selective anti-hepatitis C virus agents. <i>European Journal of Medicinal Chemistry</i> , 2016, 122, 319-325.	2.6	6
40	A Journey around the Medicinal Chemistry of Hepatitis C Virus Inhibitors Targeting NS4B: From Target to Preclinical Drug Candidates. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 16-41.	2.9	56
41	p38 MAPK and Type I Inhibitors: Binding Site Analysis and Use of Target Ensembles in Virtual Screening. <i>Molecules</i> , 2015, 20, 15842-15861.	1.7	14
42	The Pyrazolobenzothiazine Core as a New Chemotype of p38 Alpha Mitogen-Activated Protein Kinase Inhibitors. <i>Chemical Biology and Drug Design</i> , 2015, 86, 531-545.	1.5	14
43	Boosting Effect of 2-Phenylquinoline Efflux Inhibitors in Combination with Macrolides against <i>Mycobacterium smegmatis</i> and <i>Mycobacterium avium</i> . <i>ACS Infectious Diseases</i> , 2015, 1, 593-603.	1.8	21
44	Discovery of the 2-phenyl-4,5,6,7-Tetrahydro-1H-indole as a novel anti-hepatitis C virus targeting scaffold. <i>European Journal of Medicinal Chemistry</i> , 2015, 96, 250-258.	2.6	24
45	A Broad Anti-influenza Hybrid Small Molecule That Potently Disrupts the Interaction of Polymerase Acidic Protein-Basic Protein 1 (PA-PB1) Subunits. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 3830-3842.	2.9	81
46	A Comprehensive Structural Overview of p38 MAPK in Complex with Type I Inhibitors. <i>ChemMedChem</i> , 2015, 10, 957-969.	1.6	17
47	Accounting for Target Flexibility and Water Molecules by Docking to Ensembles of Target Structures: The HCV NS5B Palm Site I Inhibitors Case Study. <i>Journal of Chemical Information and Modeling</i> , 2014, 54, 481-497.	2.5	16
48	New Pyrazolobenzothiazine Derivatives as Hepatitis C Virus NS5B Polymerase Palm Site I Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 3247-3262.	2.9	35
49	The Versatile Nature of the 6-Aminoquinolone Scaffold: Identification of Submicromolar Hepatitis C Virus NS5B Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1952-1963.	2.9	43
50	Enantioresolution, stereochemical characterization and biological activity of a chiral large-conductance calcium-activated potassium channel opener. <i>Journal of Chromatography A</i> , 2014, 1363, 162-168.	1.8	20
51	Exploiting the anti-HIV 6-desfluoroquinolones to design multiple ligands. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 4658-4666.	1.4	19
52	Ethyl 1,8-Naphthyridone-3-carboxylates Downregulate Human Papillomavirus-16 E6 and E7 Oncogene Expression. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 5649-5663.	2.9	9
53	1,4-Benzothiazine ATP-Sensitive Potassium Channel Openers: Modifications at the C-2 and C-6 Positions. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4718-4728.	2.9	20
54	Structural Investigation of Cycloheptathiophene-3-carboxamide Derivatives Targeting Influenza Virus Polymerase Assembly. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 10118-10131.	2.9	51

#	ARTICLE	IF	CITATIONS
55	Computer-Aided Design, Synthesis and Validation of 2-Phenylquinazolinone Fragments as CDK9 Inhibitors with Anti-HIV-1 Tat-Mediated Transcription Activity. <i>ChemMedChem</i> , 2013, 8, 1941-1953.	1.6	32
56	Structure-Based Discovery of Pyrazolobenzothiazine Derivatives As Inhibitors of Hepatitis C Virus Replication. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 2270-2282.	2.9	40
57	Re-evolution of the 2-Phenylquinolines: Ligand-Based Design, Synthesis, and Biological Evaluation of a Potent New Class of <i>Staphylococcus aureus</i> NorA Efflux Pump Inhibitors to Combat Antimicrobial Resistance. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4975-4989.	2.9	51
58	Design, Synthesis, and Evaluation of WC5 Analogues as Inhibitors of Human Cytomegalovirus Immediate-Early 2 Protein, a Promising Target for Anti-HCMV Treatment. <i>ChemMedChem</i> , 2013, 8, 1403-1414.	1.6	18
59	6-Hydrogen-8-Methylquinolones Active Against Replicating and Non-replicating <i>Mycobacterium tuberculosis</i> . <i>Chemical Biology and Drug Design</i> , 2012, 80, 781-786.	1.5	13
60	Pyrazolo[4,3- <i>c</i> ][1,2]benzothiazines 5,5-Dioxide: A Promising New Class of <i>Staphylococcus aureus</i> NorA Efflux Pump Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 3568-3572.	2.9	82
61	Searching for innovative quinolone-like scaffolds: synthesis and biological evaluation of 2,1-benzothiazine 2,2-dioxide derivatives. <i>MedChemComm</i> , 2012, 3, 1092.	3.5	20
62	Pyridobenzothiazole derivatives as new chemotype targeting the HCV NS5B polymerase. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 866-876.	1.4	41
63	Allosteric inhibition of the hepatitis C virus NS5B polymerase: <i>in silico</i> strategies for drug discovery and development. <i>Future Medicinal Chemistry</i> , 2011, 3, 1027-1055.	1.1	39
64	Evolution from a Natural Flavones Nucleus to Obtain 2-(4-Propoxyphenyl)quinoline Derivatives As Potent Inhibitors of the <i>S. aureus</i> NorA Efflux Pump. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 5722-5736.	2.9	102
65	Synthesis and chromatographic enantioresolution of anti-HIV quinolone derivatives. <i>Talanta</i> , 2011, 85, 1392-1397.	2.9	27
66	Structural Investigation of the Naphthyridone Scaffold: Identification of a 1,6-Naphthyridone Derivative with Potent and Selective Anti-HIV Activity. <i>ChemMedChem</i> , 2011, 6, 1249-1257.	1.6	30
67	N-Benzoyl-N-methylsulfonyl anthranilates: unexpected cyclization reaction to 4-alkoxy-2,1-benzothiazines. <i>Arkivoc</i> , 2011, 2011, 165-176.	0.3	5
68	Effects of K <sup>ATP</sup> openers on the QT prolongation induced by HERG-blocking drugs in guinea-pigs. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 62, 924-930.	1.2	14
69	Studies of Anti-HIV Transcription Inhibitor Quinolones: Identification of Potent N1-Vinyl Derivatives. <i>ChemMedChem</i> , 2010, 5, 1880-1892.	1.6	26
70	Inside Cover: Studies of Anti-HIV Transcription Inhibitor Quinolones: Identification of Potent N1-Vinyl Derivatives ( <i>ChemMedChem</i> 11/2010). <i>ChemMedChem</i> , 2010, 5, 1798-1798.	1.6	0
71	The 6-Aminoquinolone WC5 Inhibits Human Cytomegalovirus Replication at an Early Stage by Interfering with the Transactivating Activity of Viral Immediate-Early 2 Protein. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1930-1940.	1.4	29
72	6-desfluoroquinolones as HIV-1 Tat-mediated transcription inhibitors. <i>Future Medicinal Chemistry</i> , 2010, 2, 1161-1180.	1.1	28

#	ARTICLE	IF	CITATIONS
73	A 1,8-Naphthyridone Derivative Targets the HIV-1 Tat-Mediated Transcription and Potently Inhibits the HIV-1 Replication. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 641-648.	2.9	122
74	A 6-Aminoquinolone Compound, WC5, with Potent and Selective Anti-Human Cytomegalovirus Activity. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 312-315.	1.4	25
75	Synthesis of 2-(Arylamino)ethanethiols via Lewis Acid Catalyzed Aminolysis of 2,2-Dimethylthiirane as Precursors of the 1,4-Benzothiazine Nucleus. <i>Synthesis</i> , 2009, 2009, 1513-1519.	1.2	2
76	2-Phenylquinolones as Inhibitors of the HIV-1 Tat-TAR Interaction. <i>ChemMedChem</i> , 2009, 4, 935-938.	1.6	18
77	Studies on anti-HIV quinolones: New insights on the C-6 position. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 667-674.	1.4	32
78	Synthesis and biological evaluation of 2-phenylquinolones targeted at Tat/TAR recognition. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 714-717.	1.0	21
79	Inhibition of Subgenomic Hepatitis C Virus RNA Replication by Acridone Derivatives: Identification of an NS3 Helicase Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 3354-3365.	2.9	54
80	Comparative In Vitro Anti-Hepatitis C Virus Activities of a Selected Series of Polymerase, Protease, and Helicase Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3433-3437.	1.4	43
81	Structure-Activity Relationship Study on Anti-HIV 6-Desfluoroquinolones. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 5454-5458.	2.9	56
82	Novel 1,4-Benzothiazine Derivatives as Large Conductance Ca <sup>2+</sup> -Activated Potassium Channel Openers. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 5085-5092.	2.9	29
83	Novel In Vivo Model for the Study of Human Immunodeficiency Virus Type 1 Transcription Inhibitors: Evaluation of New 6-Desfluoroquinolone Derivatives. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1407-1413.	1.4	19
84	Synthesis and Anti-BVDV Activity of Acridones As New Potential Antiviral Agents <sup>1</sup> . <i>Journal of Medicinal Chemistry</i> , 2006, 49, 2621-2627.	2.9	71
85	From Cromakalim to Different Structural Classes of KATP Channel Openers. <i>Current Topics in Medicinal Chemistry</i> , 2006, 6, 1049-1068.	1.0	19
86	Inhibition of cell growth and induction of apoptosis in human prostate cancer cell lines by 6-aminoquinolone WM13. <i>Oncology Reports</i> , 2005, 13, 1113.	1.2	0
87	Binding studies and GRIND/ALMOND-based 3D QSAR analysis of benzothiazine type KATP-channel openers. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 5581-5591.	1.4	21
88	Cell-dependent interference of a series of new 6-aminoquinolone derivatives with viral (HIV/CMV) transactivation. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 847-855.	1.3	50
89	Inhibition of cell growth and induction of apoptosis in human prostate cancer cell lines by 6-aminoquinolone WM13. <i>Oncology Reports</i> , 2005, 13, 1113-20.	1.2	0
90	Chemometric Studies on the Bactericidal Activity of Quinolones via an Extended VolSurf Approach. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 3193-3201.	2.9	39

#	ARTICLE	IF	CITATIONS
91	6-Aminoquinolones: photostability, cellular distribution and phototoxicity. <i>Toxicology in Vitro</i> , 2004, 18, 581-592.	1.1	20
92	Structure Modifications of 6-Aminoquinolones with Potent Anti-HIV Activity1. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 5567-5578.	2.9	45
93	Highly Potent 1,4-Benzothiazine Derivatives as KATP-Channel Openers. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 3670-3679.	2.9	48
94	New Anti-Human Immunodeficiency Virus Type 1 6-Aminoquinolones: Mechanism of Action. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 889-896.	1.4	60
95	In vitro phototoxic properties of new 6-desfluoro and 6-fluoro-8-methylquinolones. <i>Toxicology in Vitro</i> , 2002, 16, 683-693.	1.1	40
96	QSAR study and VolSurf characterization of anti-HIV quinolone library. <i>Journal of Computer-Aided Molecular Design</i> , 2001, 15, 203-217.	1.3	21
97	Velnacrine thiaanalogue as potential agents for treating alzheimer's disease. <i>Bioorganic and Medicinal Chemistry</i> , 2001, 9, 2921-2928.	1.4	16
98	(1,4-Benzothiazinyloxy)alkylpiperazine derivatives as potential antihypertensive agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2000, 10, 465-468.	1.0	34
99	Chemometric rationalization of the structural and physicochemical basis for selective cyclooxygenase-2 inhibition: toward more specific ligands. <i>Journal of Computer-Aided Molecular Design</i> , 2000, 14, 277-291.	1.3	18
100	6-Aminoquinolones as New Potential Anti-HIV Agents. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 3799-3802.	2.9	105
101	Studies on 6-Aminoquinolones: synthesis and antibacterial evaluation of 6-amino-8-ethyl- and 6-amino-8-methoxyquinolones. <i>Bioorganic and Medicinal Chemistry</i> , 1999, 7, 2465-2471.	1.4	19
102	8-Methyl-7-substituted-1,6-naphthyridine-3-carboxylic acids as New 6-desfluoroquinolone antibacterials. <i>Journal of Heterocyclic Chemistry</i> , 1999, 36, 953-957.	1.4	6
103	Design and Synthesis of Modified Quinolones as Antitumoral Acridones. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 2136-2144.	2.9	34
104	Mg <sup>2+</sup> -mediated binding of 6-Substituted quinolones to DNA: relevance to biological activity. <i>Bioorganic and Medicinal Chemistry</i> , 1998, 6, 1555-1561.	1.4	52
105	Dibenzo[1,6]naphthyridindiones as modified quinolone antibacterials. <i>European Journal of Medicinal Chemistry</i> , 1998, 33, 899-903.	2.6	8
106	Chemometric Methodologies in a Quantitative Structure-Activity Relationship Study: The Antibacterial Activity of 6-Aminoquinolones. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 1698-1706.	2.9	21
107	Synthesis and antibacterial evaluation of [1,3]benzothiazino[3,2-a]quinoline- and [3,1]benzothiazino[1,2-a]quinoline-6-carboxylic acid derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 1997, 5, 1339-1344.	1.4	22
108	Studies on 6-Aminoquinolones: Synthesis and Antibacterial Evaluation of 6-Amino-8-methylquinolones1. <i>Journal of Medicinal Chemistry</i> , 1996, 39, 436-445.	2.9	73

#	ARTICLE	IF	CITATIONS
109	Potent 6-Desfluoro-8-methylquinolones as New Lead Compounds in Antibacterial Chemotherapy1. Journal of Medicinal Chemistry, 1996, 39, 4952-4957.	2.9	54
110	6-Aminoquinolones: A New Class of Quinolone Antibacterials?. Journal of Medicinal Chemistry, 1995, 38, 973-982.	2.9	51
111	7-(Disubstituted thiazolyl)-3,5-dihydroxy-6-heptenoic/heptanoic acid derivatives as HMG-COa reductase inhibitors. Bioorganic and Medicinal Chemistry, 1994, 2, 799-806.	1.4	0
112	4 <i>H</i> -1,4-benzothioapyran-4-one-3-carboxylic acids and 3,4-dihydro-2 <i>H</i> -isothiazolo[5,4 <i>b</i> ]benzothioapyran-3,4-diones as quinolone antibacterial analogs. Journal of Heterocyclic Chemistry, 1993, 30, 1143-1148.	1.4	15
113	o-Chlorobenzenesulfonamidic derivatives of (aryloxy)propanolamines as .beta.-blocking/diuretic agents. Journal of Medicinal Chemistry, 1993, 36, 157-161.	2.9	25
114	Quinolonecarboxylic acids. 3. Synthesis and antibacterial evaluation of 2-substituted 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids related to rifloxacin. Journal of Medicinal Chemistry, 1993, 36, 3449-3454.	2.9	18
115	1,4-Benzothiazine-2-carboxylic acid 1-oxides as analogues of antibacterial quinolones. Journal of Heterocyclic Chemistry, 1992, 29, 375-382.	1.4	19
116	Symbiotic approach to drug design: N-[(4-chloro-3-sulfamoylbenzamido)-ethyl]propanolamine derivatives as $\beta$ -adrenergic blocking agents with diuretic activity. European Journal of Medicinal Chemistry, 1991, 26, 381-386.	2.6	9
117	Synthesis and $\beta$ -adrenergic blocking activity of 1,4-benzothiazine oxime ethers. European Journal of Medicinal Chemistry, 1989, 24, 479-484.	2.6	7
118	Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids. Journal of Medicinal Chemistry, 1987, 30, 465-473.	2.9	96